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INTRODUCTION 
  
 With many drugs, the basic goal of therapy is to achieve a steady 
state blood or tissue level that is therapeutically effective and nontoxic for 
an extended period of time. The design of proper dosage regimen is an 
important element in accomplishing this goal. A basic objective in dosage 
form design is to optimize the delivery of medication so as to achieve a 
measure of control for the therapeutic effect in the face of uncertain 
fluctuations in the in vivo environment where the drug release takes place. 
This is usually accomplished by maximizing drug availability, i.e., by 
attempting to attain a maximum rate and extent of drug absorption, 
however, control of drug release through formulation also implies 
controlling bioavailability to reduce drug absorption rates.1   
 Sustained release (SR) systems are defined as “Any drug delivery 
system that achieves slow release of drug over an extended period of time if 
this system provides some control as spatial, temporal or both for drug 
releases in the body and it is considered as a sustained release system”. 
 
THE SUSTAINED RELEASE CONCEPT1 
   Sustained release, sustained action, prolonged action, controlled 
release, extended action, timed release, depot, and repository dosage forms 
are terms used to identify drug delivery systems that are designed to achieve 
a prolonged therapeutic effect by continuously releasing medication over an 
extended period of time after administration of single dose. In the case of 
orally administered forms, however, this period is measured in hours and 
critically depends on residence time of the dosage form in the 
gastrointestinal tract.  
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 The goal in designing sustained or controlled delivery system is to 
reduce the frequency of dosing or to increase the effectiveness of the drug 
by localization at the site action, reducing the dose required, or providing 
uniform drug delivery. 
 If one were to imagine the ideal drug delivery system, two 
prerequisites would be required. First, it would be a single dose for duration 
of treatment, whether it is for days or week, as in infections, or for lifetime 
of the patient, as in hypertension or diabetes. Second, it should deliver the 
active entity (drug) directly to the site of action, there by minimizing or 
eliminating side effects. This may necessitate delivery to specific receptors 
or to localization to cells or to specific areas of the body.2 
 It is obvious that this imaginary delivery system will have changing 
requirements for different disease states and different drugs. Thus, we wish 
to deliver the therapeutic agent to a specific site and for a specific time. In 
other words, the objective is to achieve both spatial and temporal placement 
of drug. Currently, it is possible to only achieve both of these goals, with 
most drug delivery systems. The given pictorial representation in FIG:1 
gives an idea about the sustained drug delivery system3 
 
FIG: 1 Plasma Concentration Vs time 
profile
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FACTORS GOVERNING THE DESIGN OF DOSAGE FORM4  
 There are number of factors which may influence the design of any 
dosage form. Similarly design of sustained release dosage form is governed 
by the factors listed below in Table: 1 
 
Table:1 Factors governing the design of sustained release dosage form3 
Drug related 
Aqueous solubility 
Partition co-efficient 
Protein binding 
Molecular weight 
Drug stability 
 
Pharmacokinetic 
 
Absorption rate 
Elimination half life 
Rate of metabolism 
Dosage form index (DI) 
First pass metabolism  
Pharmacodynamic 
Therapeutic range 
Therapeutic index (TI) 
Plasma-concentration responses 
Route of administration 
Dose size 
Absorption efficiency 
Duration of action 
Pharmacological 
 
Changes in drug effect upon multiple dosing 
Sensitizing 
Tolerance 
Physiological  
Prolonged drug absorption 
Variability in GI emptying and motility 
GI blood flow 
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DRUGS SUITABLE FOR EXTENDED RELEASE FORMULATIONS1  
 Not all the drugs lend themselves to the formulation of an extended 
release product. The important factors that are to be considered in the 
choice of a drug as a candidate of SR preparations are given in Table: 2. 
 
    Table: 2 Characteristics of drugs unsuitable for peroral SR forms 
Characteristics Drugs 
Not effectively absorbed in the lower 
intestine 
Riboflavin, Ferrous salts 
Absorbed and excreted rapidly, short 
biological half lives 
Penicillin G,Furosemide 
Long biological half lives (>12 hour) Diazepam,Phenytoin 
Large doses required (>1gm) Sulfonamides  
Cumulative action and undesirable side 
effects, drugs with low therapeutic 
index 
Phenobarbitol,Digitoxin 
Precise dosage titrates to individual is 
required  
Anticoagulants, Cardiac 
glycosides  
No clear advantage for SR formulation Griseofulvin 
 
ADVANTAGES OF SR DOSAGE FORM 
¾ The frequency of drug administration will be reduced. 
¾  Patient compliance can be improved. 
¾  Drug administration can be made more convenient as well. 
¾ The blood level oscillation characteristic of multiple dosing of 
conventional dosage forms are reduced, because more even blood level 
is maintained. 
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¾ The total amount of the drug administered can be reduced, thus 
maximizing availability with a minimum. 
¾ The better control of drug absorption can be attained by reducing 
availability. 
¾ The safety margin of high potency drugs can be increased, and the 
incidence of both local and systemic adverse side effects can be 
reduced. 
¾ Overall, administration of sustained release forms enables increased 
reliability of therapy. 
 
DISADVANTAGES OF SR DOSAGE FORM 
¾ Administration of sustained release medication does not permit the 
prompt termination of therapy. Immediate changes in drug need 
during therapy, such as might be encountered if significant adverse 
effects are noted, cannot be accommodated. 
¾ The physician has less flexibility in adjusting dosage regimens. This 
 is fixed by the dosage form design. 
¾ Sustained release forms are designed for the normal population, i.e., 
on the basis of average biological half lives. Consequently, disease 
state that alter drug disposition, significant variation, and so forth are 
not accommodated. 
¾ Economic factors must also be assessed, since more costly processes 
and equipments are involved in manufacturing of many sustained 
release dosage forms. 
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MULTIPARTICULATE MODIFIED RELEASE SYSTEMS 5, 6 
 Sustained - release solid dosage form systems are available either as 
single-unit (non divided) formulation or as multiple-unit (divided) 
formulation forms. The single-unit dosage forms usually refer to where the 
drug is dissolved or dispersed throughout a solid matrix and the release of 
the drug is controlled or sustained either by incorporating a suitable filler 
within the matrix or by coating the matrix with swellable or non swellable 
polymer film(s). Interest in oral sustained release dosage forms has brought 
increasing attention to multiparticulate modified release systems. Multiple- 
unit dosage forms are essential where drug excipients or drug-drug 
physicochemical interaction is possible in a single-unit formulation. They 
are also known to have less variance in transit time through the 
gastrointestinal tract than single-unit dosage forms. These dosage forms 
usually are based on subunits such as granules, beads, pellets, or 
minitablets. They are usually delivered in hard gelatin capsules or made into 
tablets that disintegrate instantly. 
  The recent interest in multiple-unit dosage forms are a result of the 
advantages they offer over the single unit systems. For example, multiple-
unit forms offer  
 
¾ More predictable gastric emptying. 
¾ Greater statistical assurance of drug release and so more reproducible 
and constant drug concentration after oral administration. Therefore, 
inter and intra patient variability is reduced. 
¾ Gastric emptying is less dependent on the state of nutrition. 
¾ A high degree of dispersion in the digestive tract. 
¾ Less absorption variability. 
¾ Reduced risk of systemic toxicity. 
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¾ There is a greater probability of achieving total drug release from a 
multi particulate system than from a monolithic single – unit SR 
dosage form, so bioavailability can be better for multi particulate 
systems 
¾ A lesser risk of dose dumping.  
¾ Single unit system may fail to release the maintenance dose from the 
slow release core. This point can be critical for low solubility of 
drugs and/or if there is an absorption window where absorption take 
place in a limited region of the gastrointestinal tract. 
¾ The multiple-unit forms are also more suitable for formulations with 
acid-sensitive drugs (i.e., erythromycin). 
 
On the other hand, multiple-unit preparations exhibit some disadvantages. 
¾ Their manufacturing is more complicated.  
¾ More expensive. 
¾ The filling of gelatin capsules is difficult to accomplish especially in 
the case where different subunits are involved. 
¾ The preparation process of tablets necessitates extra care and fine 
adjustments of tabletting machines.  
 
 Although the debate on the particular advantages of two 
formulations (single- and multiple-unit) has been going on for a long time 
in the literatures. It has not produced any definite conclusion on the 
performance of those formulations until now and the differences in behavior 
are controversial.  
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Examples of multi particulate modified release tablets  
  The compaction of beads is a challenging area and only a few 
multiple unit containing tablet products are available such as Beloc ZOK 
which releases metoprolol succinate with zero order kinetics and Antra 
MUPS (Astra Zeneca Sodertalje, Sweden) is a multiple unit pellet system 
for the proton pump inhibitor omeprazole.  
 
MICROENCAPSULATION 5 
 A process in which very thin coatings of polymeric material(s) are 
deposited around particles of solids or droplets of liquid. 
 Different terms for solid particle systems are employed in drug 
delivery among them pellets, beads, microcapsules, microspheres, 
millispheres are few. The terminologies of most relevant multiparticulate 
systems are provided here. 
 Pellets can be defined as “Small, free flowing spherical particles 
manufactured by agglomeration of fine powders or granules of drug 
substances and excipients using appropriate processing equipment.” The 
size of these particles are usually between 0.5 and 1.5 mm. Sphericity and 
intra granular porosity are the two important quality attributes of pellets. 
The terms ‘spherical granules’ and ‘beads’ have been applied 
interchangeably to pellet system. 
 Microspheres are solids approximately spherical particles ranging in 
size from 1 to 1000 µm. They are made of polymeric, waxy, or other 
protective materials, that are biodegradable synthetic polymers and 
modified natural products such as gums, proteins, waxes etc. 
 Microsphere: The entrapped substance is dispersed throughout the 
microsphere matrix. 
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 Microcapsule: The entrapped substance is completely surrounded 
by distinct capsule wall.  
  
 The similarities between microsphere and microcapsules are clear 
and illustrations of these particles are shown in FIG: 2 
 
 
FIG: 2 (A) Microcapsule (B) Microsphere 
 
Encapsulation methods7  
 Two major classes of encapsulation methods have evolved, viz 
chemical and physical. The first class of encapsulation involves 
polymerization during the process of preparing the microcapsules. 
Examples of this class are usually known by the name of interfacial 
polymerization or in situ polymerization. The second type involves 
controlled precipitation of a polymeric solution where in physical changes 
usually occur.  
 
 The precipitation and/or gelation listed in Table: 3 cover many 
techniques. One example is the precipitation of water soluble polymers such 
as gelatin with water miscible solvents such as isopropanol. Other examples 
include the precipitation of ethyl cellulose from cyclohexane by cooling, 
and the gelation of sodium alginate with aqueous calcium salt solutions. In 
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all cases the objective is to precipitate a performed polymer around the core 
(sometimes a multi- particulate) to cause encapsulation. 
 
Table: 3   Methods of Precipitation and/or Gelation7 
 
Process 
 
Coating material 
 
Suspended medium 
Interfacial 
polymerization 
Water-soluble and insoluble 
monomers 
Aqueous/organic 
solvents 
Complex 
coacervation 
Water-soluble polyelectrolyte Water 
Simple Coacervation Hydrophobic polymers Organic solvents 
Thermal denaturation Proteins Organic solvents 
Salting out Water-soluble polymer Water 
Solvent evaporation Hydrophilic or hydrophobic 
polymer 
Organic or Water 
Hot melt Hydrophilic or hydrophobic 
polymer 
Aqueous/organic 
solvents 
Solvent removal Hydrophilic or hydrophobic 
polymer 
Organic solvents 
Spray drying Hydrophilic or hydrophobic 
polymer 
Air, nitrogen 
Phase separation Hydrophilic or hydrophobic 
polymer 
Aqueous/organic 
solvents 
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POLYMER BASED DRUG DELIVERY SYSTEM8: 
 There has been growing interest in polymer based bioadhesive drug 
delivery systems. One of the goals of such systems is to prolong the 
residence time of a drug carrier in the Gastro Intestinal Tract (GIT). The 
bioadhesive bond can be of a covalent, electrostatic, hydrophobic or 
hydrogen bond nature. Ionic polymers are reported to be more adhesive 
than neutral polymers, and an increased charge density will also give better 
adhesion suggesting that the electrostatic interactions are of great 
importance. Except for the oesophagus, the entire GI tract including the 
stomach is covered with a continuous layer of insoluble mucus gel. The 
mucus gel mainly consists of glycoproteins, and due to their content of ester 
sulphate and sialic acid groups, the mucus layer has an overall strong net 
negative charge. The mucus layer has been considered as a possible site for 
bioadhesion and drug delivery by several groups. 
 
Natural polymers 
 Recently, the use of natural polymers in the design of drug delivery 
formulation has received much attention due to their excellent 
biocompatibility, biodegradability, non - toxicity, and easy in availability9.  
 
Polymers as carriers used in drug delivery system 10 
 The different types of polymers for extended release preparations are 
given below:  
 
Biodegradable Polymers:  
 The biodegradable polymers comprised of monomers linked to one 
another through functional groups and have unstable linkages in the 
backbone. They are biologically degraded or eroded by enzymes or 
generated by surrounding living cells. 
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•  Natural 
 Albumin, Alginate, Collagen, Starch, Chitosan, Dextran, Casein, 
Gelatin, Fibrinogen, etc. 
•  Synthetic 
 Poly alkyl-cyanoacrylate, Poly ethyl-cyanoacrylate, Poly amino 
acids, Poly amides, Poly acryl amides, etc. 
•  Aliphatic Polyesters 
 Poly (malic acid), Poly (glycolic acid), Poly (hydroxyl butyrate), 
Poly (lactic acid), Poly Vinyl Alcohol (PVA) etc. 
Non-Biodegradable Polymers : 
 Poly Ethylene Vinyl Acetate (EVA), Poly Ether Urethane (PEU), 
Cellulose Acetate, Poly Vinyl Chloride (PVC), Ethyl Cellulose,etc 
 
 In recent years a large number of biodegradable polymers have been 
investigated for their potential use as drug delivery systems. Among them, 
sodium alginate and chitosan are very promising and have been widely 
exploited in pharmaceutical industry for sustained drug release. 
Polysaccharides such as alginic acid, agar, chitin and chitosan have been 
used to agglomerate drugs for controlled drug delivery systems. 
  Chitosan is a naturally occurring polysaccharide comprising 
glucosamine and N-acetyl glucosamine with unique polycation 
characteristics. The poly cationic nature of chitosan leads to a strong 
interaction with negatively charged alginate. When alginate is dropped into 
chitosan solution, the electrostatic interaction of carboxylic groups of 
alginate with the amine groups of chitosan results in the formation of a 
membrane on the surface of sodium alginate and improves the stability and 
drug content8. This process has been widely used in the preparation                     
of alginate–chitosan membranes with a solid calcium–alginate gel core.                  
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There are many advantages of the chitosan coating, such as the 
improvement of drug loading and bioadhesive property, as well as the 
prolonged drug release properties etc. 
  Alginate (ionic, hydrophilic polymer) is a negatively charged 
polysaccharide with high charge density and has been reported to be 
bioadhesive. Among polyanionic polymers, alginate has been widely 
studied and applied for its possibility to modulate the release, according to 
the properties of its carboxyl groups as well as its biodegradability and 
absence of toxicity. Alginate is a naturally derived anionic polysaccharide 
mainly from algae belonging to the family phaeophyceae. Alginic acid is an 
algal polysaccharide and a species of polycarboxylic acid. Alginate consists 
of two sugar moieties β-D-mannuronic acid and α -L-guluronic acid which 
exists either in blocks or random sequences and their relative proportions 
determine the biofunctional properties of alginic acid. Alginate is known to 
form complexes with divalent cations, such as Ca2+, Ba2+, and Sr2+ in 
aqueous solution. Depending upon the composition of two sugar residues 
and sequential distribution within the molecules, the complexes form either 
precipitates or hydrogels. Guluronic acid blocks are known to form a rigid 
buckled structure, the so-called ‘egg-box’ array, in which chelating calcium 
ions are nestled in the aqueous environment of the ordered gel structure due 
to the spatial arrangements of guluronic block oxygen atoms of carboxyl 
and hydroxyl groups 11.  
 Alginate has been widely used as food additive, a tablet disintegrator 
or gelation agent, and the mechanism of its gelation have been extensively 
investigated. When an aqueous solution of sodium alginate (SA) is added 
drop wise to an aqueous solution of calcium chloride, spherical alginate 
beads with regular shape and size are produced, since an insoluble calcium 
alginate matrix is formed by the cation exchange between sodium and 
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calcium ions. Alginates are known to form reticulated structure when in 
contact with calcium chloride ions and this characteristic has been used to 
produce SR particulate systems for a variety of drugs12. 
GEL FORMATION (GENERAL MECHANISM): 
 A gel, in classical colloid terminology, is defined as a system which 
owes its characteristic properties to a cross linked network of polymeric 
chains which form at the gel point. A considerable amount of research has 
been carried out in recent years to elucidate the nature of the cross-links and 
determine the structure of alginate gels. Alginate beads can be prepared by 
extruding a solution of sodium alginate containing the desired drug or 
protein, as droplets, into a divalent cross linking solution such as Ca2+, Sr2+, 
or Ba2+. Monovalent cations do not induce gelation while Ba2+ and Sr2+ ions 
produce stronger alginate gels than Ca2+. Other divalent cations such as 
Pb2+,Cu2+,Cd2+,CO2+, Ni2 +, Zn2+and Mn2+ will also cross link alginate gels 
but their use is limited due to their toxicity. The gelation and cross linking 
of the polymers are mainly achieved by the exchange of divalent cations 
and stacking of these guluronic acids with the divalent cations, and the 
stacking of these guluronic groups to form the characteristic egg – box 
structure13 shown in Fig:3 
 
     
 FIG: 3 Schematic representation of the egg-box association of the poly-l-L-guluronate 
sequences of alginate cross linked by calcium ions. The left section of the figure shows conversion 
of random coils to buckled ribbon like structures which contain arrays of Ca2+ ions. The extreme 
right section shows the proposed stereochemistry of Ca2+ ion complexation. The oxygen atoms 
involved in the coordination sphere are shown as filled circles. 
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LARGE BEAD PREPARATION 
 In general, beads greater are than 1.0 mm in diameter which can be 
produced by using a syringe with a needle or a pipette. Sodium alginate 
solution that contains solubilized drug or protein is transferred drop wise 
into a gently agitated divalent cross linking solution. The diameter of the 
beads formed is dependent on the size of the needle used and the viscosity 
of the alginate solution. A larger diameter needle and higher viscosity 
solutions will produce larger diameter beads. The viscosity of SA can also 
influence the shape of the microbeads produced. The beads become more 
spherical as the concentration of SA increased. However, in general SA 
solutions of greater than 5% are difficult to prepare. 
 Since gelation occurs in an aqueous environment, alginate is a 
promising material as a food additive, drug formulation and useful even for 
encapsulation of living cells to protect them from immune responses. 
Utilizing this stable complex formation with divalent cations, alginate gels 
have been utilized for investigation of cells are considered to be the ultimate 
system for the pulsatile release of biologically active compounds. 
 Formulation of delivery devices for protein and peptide drugs under 
aqueous conditions are desirable to avoid the undesirable decrease of 
bioactivities which may occur when using organic solvents and/or heat 
during formulations. Since relatively stable alginate gels can be formed in 
aqueous environments through chelation or complexation, which are more 
promising delivery of matrixes for bioactive compounds.  
 It has been suggested that the cross links were caused either by ionic 
bridging of two carboxyl groups on adjacent polymer chains via calcium 
ions or by chelation of single calcium ions by hydroxyl and carboxyl groups 
on each of a pair of polymer chains7. Although these bonds may play a role 
in the gelation mechanism, which are not sufficiently energetically 
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favorable to account for the gelation of alginate. It has been shown on the 
basis of fiber diffraction data and model-building calculations that the shape 
of both polymannuronic acid segments and the polygulutended, and that 
these extended ribbons can stack together in sheets. On the basis of these 
data and the properties of gels, it has been suggested that the cooperative 
association of either polymannuronic acid segments or polyguluronic acid 
segments are involved in the formation of the cross-linked network of 
polymer chain7. 
 This technique has shown attractive applications in different fields, 
including cell immobilization, owing to its mild operative conditions. As 
the encapsulation method is mild, and done at room temperature in aqueous 
medium, several sensitive drugs, proteins, living cells, enzymes, 
spermatozoa etc. have been successfully encapsulated through alginate 
beads. 
 The primary structure of the alginates depends on the producing 
species, and for the marine species seasonal and geographical changes 
might result in variations in alginates extracted from the same species. The 
polymer is known to form a physical gel by hydrogen bonding at low pH 
(acid gel) and by ionic interactions with polyvalent cations such as calcium, 
the cation acting as a cross linker between the polymer chains. The 
viscosity and primary structure of the polymer are important features 
determining its swelling and gelling properties14. 
 At neutral pH, sodium alginate is soluble and hydrates to form 
viscous solutions, but below pH 3, alginic acid, water swellable but 
insoluble, which is rapidly formed. Since the hydration characteristics of the 
polymer and the subsequent physical properties of the hydrated gel layer 
may critically influence drug release15.  
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 When CA beads are treated with 0.1M HCl, alginate gets hydrolyzed 
to lower molecular weight fractions of alginic acid. Due to conversion of 
COO- group into unionized carboxylic group, the electrostatic attraction 
between Ca2+ ions and COO- ions in the egg-box junction almost 
disappears. Moreover, there may occur ion-exchange between H+ ions 
(presence in the external HCl solution) and free Ca2 + ions inside the beads. 
Thus a reduced Ca2+ ions concentration within the beads results in a weaker 
Ca2+ cross linked beads when put in phosphate buffer at pH 7.4. Therefore, 
the acid-treated beads are a loosely cross linked structure containing more 
soluble alginate as constituent. When such beads are put in the phosphate 
buffer of pH 7.4, the beads swell at faster rate but do not attain a higher 
water uptake value due to loosely bound structure of the beads which is 
unable to retain large amount of water within the matrix. Moreover, there is 
possibility of ion-exchange between H+ ions produced due to ionization of 
carboxylic groups in the buffer of pH. 
 A group of scientist developed a method of enclosing viable cells, 
tissues, and other labile biological substances within a semi permeable 
membrane. Preliminary in vitro studies of several types of 
microencapsulated cells and tissues (red blood cells, sperm cells, hepatica 
cells, hepatocytes, pancreatic endocrine tissues, and islets) were described 
by them. Essentially, the process involves suspending the living cells or 
tissues in sodium alginate solution. The cell or tissue suspension is extruded 
through a device producing micro droplets which fall into a calcium 
chloride solution and form gelled microbeads with the cells or tissues 
entrapped. These cell-containing, gel micro beads are next treated with a 
solution of polysine which displaces the surface layer of calcium ions and 
forms a permanent polysalt shell or membrane. Finally, the interior calcium 
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alginate is “liquefied,” either to stay in or to come out (depending on 
molecular weight and size of the starting alginate) of the capsule with a 
calcium sequestrant such as buffered citrate solution. 
 Gohel et al7., prepared diclofenac sodium microspheres by using 
sodium alginate as a polymer and CaCl2 as a cross linking agent. In this 
investigation stirring speed, concentration of cross linking agent and heavy 
liquid paraffin were studied, on the time required for 80% drug dissolution. 
A statistical model with significant interaction terms was derived to predict 
t80 and the drug was released by diffusion of anomalous type. The results of 
multiple linear regression analysis and F value statistics revealed that, 
obtaining of controlled drug release and the microspheres were to be 
prepared using relatively lower stirring speed.  
 Literature reports indicate widespread use of sodium alginate for 
achieving sustained release of drugs, targeting gastric mucosa, and 
increasing the bioavailability of drugs because of sodium alginate’s ability 
to form a stable and bioahesive gel with calcium ions13. 
 Alginate also has several unique properties that have enabled it to be 
used as a matrix for the entrapment and/or delivery of a variety of proteins, 
macromolecules and cells. 
HIGHLIGHTS OF ALGINATE BEADS16 
¾ A relatively inert aqueous environment within the matrix. 
¾ A mild room temperature encapsulation process free of organic 
solvents. 
¾ A high gel porosity which allows for high diffusion rates of 
macromolecules.  
¾ The ability to control this porosity with simple coating  procedures.  
¾ Dissolution and biodegradation of the system under normal 
physiological conditions.  
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LITERATURE REVIEW 
 Parul Trivedi. et al17., (2008) in their work “Preparation and 
characterization of Aceclofenac microspheres” reported that 
microspheres were prepared by o/w emulsion solvent evaporation technique 
using Eudragit [S 100, RL 100 and RS 100] to provide controlled release 
and minimizes local side effects by avoiding the drug release in the upper 
gastro intestinal tract. Prepared microspheres were subjected to 
micromeritic evaluation, drug loading studies, and in vitro drug release stud 
ies. The drug polymer concentration in the dispersed phase influence the 
particle size and drug release properties and all the formulations at higher 
pH follow the Matrix-Higuchi model. 
 Das MK. et al18., (2008) in their work “Furosemide loaded 
alginate microspheres prepared by ionic cross linking technique: 
morphology and release characteristics” reported that entrapment 
efficiency and particle size increased with the increased sodium alginate 
concentration. The kinetic modeling of the release data indicate that 
furosemide release from the alginate microspheres follow anomalous 
transport mechanism after an initial lag period when the drug release 
mechanism was found to be fickian diffusion controlled. 
 
 Srinatha A. et al19., (2008) in their work “Ionic cross - linked 
chitosan beads for extended release of Ciprofloxacin: In vitro 
characterization” reported that chitosan beads loaded with Ciprofloxacin 
HCl were prepared with ionic cross  linking with sodium tripolyphosphate. 
High drug load was achieved within the bead with a short curing time. The 
release was increased with increasing concentrations of ciprofloxacin and 
decreasing proportion of chitosan. The drug release follows by non- fickian 
release mechanism. 
Chapter 2 Literature Review 
 20
 
 Li Jun. et al20., (2007) in their work “Preparation of procaine 
haemoglobin microcapsules of chitosan-sodium alginate” reported that 
microcapsules were prepared by using an emulsification gelation method. 
Microcapsules possess a relatively narrow and normal Gaussian 
distribution. The procaine hemoglobin released from microcapsules were 
extended for more than one month.Chitosan-sodium alginate hemoglobin 
microcapsules were expected to become an artificial oxygen carrying 
therapeutic agent with SR for intravenous injection. 
 
  Shishu. et al21., (2007) in their work “Stomach specific drug 
delivery of 5-Fluorouracil (5-FU) using floating alginate beads” reported 
that a multiple –unit type oral floating dosage form (FDF) was developed to 
prolong gastric residence time, target stomach cancer, and increase drug 
bioavailability. The beads containing higher amounts of calcium carbonate 
demonstrated instantaneous, complete and excellent floating ability over a 
period of 24 hours. The optimized formulation was subjected to in vivo anti 
tumor studies and results indicate that FDF performed significantly better 
than the simple tablet dosage form.  
 
  Tamizharasi S. et al22., (2007) in their work “Formulation, 
characterization and In-vitro release kinetics of Aceclofenac loaded 
poly (ε-caprolactone) microspheres” reported that drug to carrier ratio-
(1:4) showed highest drug entrapment and the drug released upto 15 hour 
and found to be sustained. There was no interaction between drug and 
polymer. 
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  Arshia Sheriff. et al23., (2007) in their work “Entrapment of 
Andrographolide in cross linked alginate pellets:I Formulation and 
evaluation of associated release kinetics” reported that andrographolide 
can be converted to bitterless multiple unit dose oral delivery systems by 
utilizing the technique of ionotropic gelation. Several processing parameters 
were analyzed and finally pellets prepared by 2.5%w/v of sodium alginate 
into a 2%w/v solution of calcium chloride using 20 gauze flat tip needle and 
dried using a hot air oven at 60°C for 6 hours. Pellets with varied                  
drug: polymer ratios were prepared and analyzed for release kinetics it was 
found to be best described by the korsemeyer – peppas equation. The 
formed pellets were completely bitterless with good entrapment efficiency 
and a maximum release of 86% of andrographolide preferably away from 
the stomach. 
 
 Thaned Pongjanyakul. et al24.., (2007) in their work “Xanthan 
alginate composite gel beads: Molecular interaction and in vitro 
characterization” reported that composite beads consisting of Xanthan 
Gum (XG), Sodium Alginate (SA) and beads of Diclofenac Calcium 
Alginate (DCA) incorporated with different amounts of XG were prepared 
by using ionotropic gelation method. Molecular interaction and physical 
properties of composite and XG-DCA beads were evaluated. XG could 
form inter molecular hydrogen bonding with SA in the composite beads 
with or without Diclofenac Sodium (DS). Higher the content of XG in the 
DCA beads increased the drug entrapment efficiency and release rate of 
drug. It can be concluded that XG could modulate physicochemical 
properties and drug release of the DCA beads, which based on the existence 
of molecular interaction between the XG and SA. 
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 `Shende PK. et al25., (2007) in their work “Formulation and 
characterization of alginate-gelatin beads for controlled release of 
Glipizide” reported that modification in matrix structure of alginate could 
be done by addition of gelatin and the alginate-gelatin matrix does not 
interfere with glipizide. Glipizide seems not to be involved in the cross 
linking reaction, which appears to occur only between gelatin, alginate and 
formaldehyde which were used as cross-linking agent. 
 
 Manjunatha KM. et.al26., (2007) in their work “Design and 
Evaluation of Diclofenac sodium controlled drug delivery system” 
reported that the immediate release component and controlled release 
component were prepared by using mannitol and sodium alginate 
respectively. Poly vinyl pyrolidine and mannitol were used as carriers for 
drug in preparing solid dispersion and this solid dispersion form shown 
increased the solubility of the drug. The prepared controlled release beads 
were sufficiently hard and sustained the release of drug for long duration. 
 
 Sahoo SK. et al27., (2007) in their work “Formulation and in vitro 
evaluation of alginate beads of Aceclofenac by ionotropic gelation 
technique” reported that the drug loaded beads showed 70 to 80 % of drug 
entrapment, which was found to increase with increase in sodium alginate 
concentration. The release of aceclofenac was found to be affected both by 
concentration of polymer and cross linking agent (calcium chloride). 
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 Raida S Al-kassas. et al28., (2007) in their work “Controlling of 
systemic absorption of Gliclazide through incorporation into alginate 
beads” reported that alginates have the advantages of swelling and 
mucoadhesive properties, so that it could be used to improve the oral 
delivery of the antidiabetic agent gliclazide. The swelling behavior of the 
beads strongly dependent on the polymer concentration in the formulation 
and pH of the medium.   
 
 Thaned pongjanyakul. et al29., (2006) in their work “Modulation 
of drug release from glyceryl palmitostearate-alginate beads via heat 
treatment” reported that incorporation of glyceryl palmitostearate (GPS) 
into the diclofenac calcium alginate (DCA) beads increased particle size 
and entrapment efficiency of diclofenac sodium (DS), but decreased water 
uptake in distilled water and DS release rate. The heat treatment caused the 
DCA beads to be irregular shape particles and to possess higher water 
uptake. A slower release rate of DS in distilled water was found because of 
interaction of DS  and alginate polymer matrix, a restriction of water 
sorption into the inside region of the beads, which caused by the shrinkage 
after heating. 
 
 Sameer sharma. et al30., (2006) in their work “Low density 
multiparticulate system for pulsatile release of Meloxicam” reported that 
floating pulsatile drug delivery system was developed using porous calcium 
silicate (Florite RE) and sodium alginate, for time and site specific drug 
release of meloxicam. Drug adsorbed Florite RE powder was used to 
prepare calcium alginate beads by ionotropic gelation method, using 32 
factorial designs and evaluated. The floating time was controlled by density 
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of beads and hydrophobic character of drug. A pulsatile release of 
meloxicam was demonstrated by a simple drug delivery system which could 
be useful in chronopharmaco therapy of rheumatoid arthritis.  
 
 Yagnesh L.Patel. et al31 ., (2006) in their work “The effect of drug 
concentration and curing time on processing and properties of calcium 
alginate beads containing metronidazole by response surface 
methodology” reported that preparation of calcium alginate beads 
containing metronidazole using 32 factorial design, with drug concentration 
and curing time as variables. Entrapment efficiency decreased with decrease 
in polymer concentration and increasing in curing time. In acidic medium, 
the swelling and drug release properties were influenced by drug solubility, 
where as in basic medium these properties were governed by the gelling of 
polymer and exhibited curvilinear and quadratic functions of both the 
variables respectively. 
 
 Satit Puttipipatkhachorn. et al32., (2005) in their work “Molecular 
interaction in alginate beads reinforced with sodium starch glycolate or 
magnesium aluminum silicate and their physical characteristics” 
reported that the additives Sodium Starch Glycolate (SSG) or Magnesium 
Aluminum Silicate (MAS) could improve the entrapment efficiency of 
Diclofenac Calcium Alginate (DCA) beads. The swelling and water uptake 
of the beads depend on the properties of incorporated additives. The SSG-
DCA beads showed a higher water uptake and swelling than MAS-DCA 
beads. The release kinetic of the beads in pH 6.8 phosphate buffer was 
swelling controlled mechanism, while that in distilled water followed 
Higuchi’s model. 
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 Gohel MC. et al33., (2005) in their work “Preparation and 
formulation optimization of sugar crosslinked gelatin microspheres of 
Diclofenac Sodium” reported that sugar (e.g glucose, fructose) can induce 
cross linking of gelation for the preparation of modified release 
microspheres. The microspheres which were prepared by emulsion 
crosslinking method revealed that, the parameters such as drug to gelatin 
ratio, volume of light liquid paraffin and stirring rate were found to affect 
the morphology and drug release of microspheres. 
 
 Anil.K.Anal. et al34., (2005) in their work “Chitosan alginate 
multilayer beads for controlled release of Ampicillin” reported that 
ionotropic gelation was used to prepare single and multi layer beads of 
ampicillin using various combinations of chitosan and Ca2+ as cationic 
components and alginate, polyphosphate as anions. Beads prepared with 
higher concentrations of chitosan entrapped more ampicillin. Single and 
multilayer chitosan alginate beads release faster than polyphosphate cross  
linked multi layer beads and it offers an opportunity for controlled 
gastrointestinal passage of compounds with low molecular weight like 
ampicillin. 
 
 Dandagi PM. et al35., (2004) in their work “Microencapsulation of 
Verapamil Hydrochloride by Ionotropic gelation technique” reported 
that, increased in speed of rotation of calcium chloride (counter-ion) 
solution, leads to decreased in pellet size. Also it was found that with the 
increase in harvesting time, the pellet formed in turn decreased the drug 
entrapment efficiency. The release of the drug from micro pellets was found 
to be following non-fickian diffusion mechanism, which accounts for the 
prolonged release of verapamil hydrochloride. 
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 Mishara. et al36., (2003) in their work “Development of chitosan – 
alginate microcapsules for colon specific delivery of Metronidazole” 
reported that microcapsules prepared by calcium chloride cross linking 
method with different concentration of sodium alginate and chitosan. Then 
they were treated for three different coating with reduced molecular weight 
chitosan, guar gum and enteric coatings with cellulose acetate pthalate. 
Chitosan concentration significantly affected the strength and flexibility of 
membrane. Drug loading was decreased with increase in the weight of 
either encapsulating polymer or chitosan and different coatings. In vitro 
drug release was found to be decreased with increasing chitosan and sodium 
alginate concentrations. Among the three coatings reduced molecular 
weight chitosan coating gave much lower drug release and exhibit colon 
specificity. 
 
 Gonzalez-Rodriguez ML. et al37., (2002) in their work “Alginate 
/chitosan particulate systems for sodium Diclofenac Release” reported 
that microspheres were prepared by ionic gelation (Ca2+ and Al3+) and 
characterized by electron microscopy and differential scanning calorimetry. 
The release of diclofenac sodium was prevented at acidic pH, while it was 
complete in a few minutes when pH is raised up to 6.4 and 7.2.The alginate 
/ chitosan ratio and nature of gelifying cation allow a control of the release 
rate of the drug.    
 
 Bhupender Singh. et al38., (2002) in their work “Design, 
development and optimization of controlled release microcapsules of 
Diltiazem Hydrochloride” reported that microcapsules were formulated as 
per factorial design taking rate controlling coat polymer and emulgent that 
is ethylcellulose and span 80 respectively. The release of drug follows 
fickian drug release. The release was found to be quite regulated for 
controlled release purpose (t80% ≈9.5hr) with little dose dumping (release 
upto 16hr≈99%). 
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 Shymala Baskaran. et al39., (2000) in their work “Preparation and 
evaluation of alginate – chitosan beads” reported that chitosan reacts with 
sodium alginate in the presence of tripolyphosphate for beads formation. 
diltiazem HCl was used as the model drug. Spherical beads were produced 
with diameter in the range of 400-600µm.The encapsulation efficiency was 
found to be 80-90% and there was a rapid initial drug release phase 
followed by a second release phase, but when glutaraldehyde or pectin is 
added the burst effect disappeared and they also decreased the percentage 
release of drug from the beads. 
 Lin sy. et al40., (1992) in their work “Calcium alginate beads as 
core carriers of 5–Amino Salicylic Acid” reported that the utilization of 
calcium alginate beads as core carriers for delayed dissolution followed by 
burst release as a potential method of intestinal site specific drug delivery 
was investigated. 5–amino salicylic acid was spray coated on dried calcium 
alginate beads and then coated with different percentages of enteric coating 
polymer and /or sustained release polymer. This dosage form provides the 
possibility to deliver drug to the lower intestinal tract with minimal early 
release followed by sustained release in the colon.  
 Chowdary KPR. et al41., (1989) in their work “Studies on 
microencapsulation by calcium alginate” reported that method based on 
emulsification of a solution of sodium alginate containing the drug in an 
immiscible liquid medium followed by  curing with calcium chloride to 
result in spherical calcium alginate microcapsules were reported. Aspirin, 
diazepam and nitrofurantoin were encapsulated by this method. The 
microcapsules were found to release the drug slow and spread over 
extended period of time. The release mechanism was found to be of 
diffusion type.  
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SCOPE OF THE WORK 
 Treatment for an ailment by the physician mostly involved drug 
substances. The use of drug substances had become inevitable in the 
modern days. The major problems faced by patients in taking the 
medications are to be overcome by altering the design of dosage form or 
properties of the drug moiety. 
 
 The scope of any formulation primarily focuses on safety and 
efficacy of the drug delivery system. Now the focus has been slightly 
moved to the patient’s convenience and acceptance. Where still the safety 
and efficacy remain integrated with design. 
 
  Recent research efforts through out the world have resulted in 
significant development of novel drug delivery systems. Among the 
systems one of the common methods of controlling the rate of drug release 
is microencapsulation and resulting beads have gained good acceptance as a 
process to achieve the sustained release. 
 
 There has been growing interest in the use of natural polymers as a 
drug carrier due to their biocompatibility, biodegradability, non-toxicity and 
easy in availability. Alginates, which are naturally occurring 
polysaccharides obtained from marine brown algae have received much 
attention ass a vehicle for sustained drug delivery. 
 
 The formation of calcium alginate beads by ionotropic gelation was 
achieved by dropping the drug containing sodium alginate dispersion into 
calcium chloride bath. Calcium induced alginate gel beads have developed 
in recent years as a unique vehicle for drug delivery systems. 
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ALGINATE BEADS HAVE THE FOLLOWING ADVANTAGES 42  
    
¾ Alginate is known to be nontoxic as taken orally and to protect the 
mucous membrane of the upper gastrointestinal tract from the 
irritation of chemicals.  
¾ Since dried alginate beads have the property of reswelling, they can 
act as a sustained -release system. 
¾ Since the property of reswelling is susceptible to the environmental 
pH, acid-sensitive drugs incorporated into the beads would be 
protected from gastric juice. 
 
 Therefore, drug-loaded alginate beads might provide these 
advantages for non - steroidal anti-inflammatory drugs (NSAIDs) such as 
aceclofenac used extensively in the treatment of rheumatoid arthritis, 
osteoarthritis and ankylosing spondylitis. Aceclofenac is one of the 
emerging NSAID molecules and having short biological half – life 4 hours, 
minimizes local side effects by avoiding the drug release in the upper gastro 
intestinal tract dosing frequency is more than one time which makes it more 
potential candidate for developing for sustained release. 
 
 Much attention has received the chitosan–alginate polyelectrolyte 
complex that has been studied thoroughly. Chitosan is used either as a 
means of coating alginate beads in order to alter the diffusion rate of the 
encapsulated substances. The behavior of calcium–alginate beads treated 
with chitosan in media that imitate the gastrointestinal fluids has been 
studied by several researchers. 
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OBJECTIVE 
 
 The use of natural polymers as drug carriers is one of the main 
objectives of recent researchers dealing with long acting dosage forms. 
Among them sodium alginate has been widely studied and applied for its 
possibility to modulate the release, according to its properties of its 
carboxyl groups by addition of multivalent ions as well as its 
biodegradability and absence of toxicity. 
 Aceclofenac is NSAID used extensively in the rheumatoid arthritis, 
osteoarthritis and having short biological half life of 4 hours, minimizes 
local side effects by avoiding the drug release in the upper gastro intestinal 
tract and dosing frequency more than one time make it an ideal candidate 
for sustained release multi particulate drug delivery system. 
 In this present study alginate beads containing aceclofenac were 
prepared by using sodium alginate a natural, hydrophilic polymer and 
calcium chloride as cross – linking agent. The influence of  
¾ The concentration of sodium alginate 
¾ Concentration of cross linking agent 
¾ Different curing time intervals 
¾ Different cross linking agents and 
¾   Addition of chitosan to calcium chloride were studied with,   
  IR and DSC for Drug interactions studies, Physical characterization 
of the formulations by optical microscope, Scanning Electron Microscope, 
and X-Ray Diffractrometry to characterize the bead.  The formulations were 
further analysed for encapsulation efficiency, in vitro drug release and 
kinetics studies. 
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PLAN OF THE WORK 
 
 The work entitled, “FORMULATION, PHYSICAL 
CHARACTERIZATION AND IN VITRO RELEASE STUDIES OF 
ACECLOFENAC ALGINATE BEADS PREPARED BY 
IONOTROPIC GELATION FOR SUSTAINED RELEASE” was 
planned an following in an aim to achieve the objective described earlier. 
The work was carried out for a period of 9 months (May 2008 to January 
2009) which was divided into three phases like 
 
Phase I (May - June 2008) 
1. Literature survey. 
2. Identification of the objective for the current study. 
3. Optimization of the parameters. 
 
Phase II (July - December 2008) 
1. Preparation of standard graph for the drug. 
2. Preparation of alginate beads by ionotropic gelation method. 
3. Evaluation of the Physical Characteristics. 
 3.1  Compatibility study using Infra Red (IR) spectroscopy and  
  Differential Scanning Calorimeter (DSC). 
 3.2  Size and size distribution analysis by using an Optical   
  Microscope. 
 3.3  Surface morphology by using Scanning Electron   
  Microscope (SEM). 
 3.4  Analysis of samples by using X – Ray Diffractometer (XRD). 
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4. Drug content and release studies 
 4.1  Drug entrapment efficiency. 
 4.2 In vitro drug release analysis. 
 
5. Kinetics of drug release from the formulations using 
 5.1 Zero order release.   
 5.2 First order release.  
 5.3   Higuchi’s model. 
  5.4 Korsmeyer’s model. 
 
Phase III (January 2009) 
1. Compilation and preparation of reports. 
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MATERIALS 
Name of the materials Name of the company 
Aceclofenac (gift sample) Anglo French drug industries Ltd, Bangalore 
Sodium alginate AR Hi media biosciences Ltd, Mumbai. 
Calcium chloride AR S.D.Fine chemicals Ltd, Mumbai 
Aluminium Sulphate AR Hi media Laboratories, Mumbai 
Barium chloride AR Qualigens Fine chemicals Ltd, Mumbai 
Chitosan AR Fluca Biochemica. Ltd, Switzerland. 
(Viscosity 200-400 mPa.s) 
Methanol AR S.D.Fine chemicals Ltd, Mumbai 
 
EQUIPMENTS USED 
Name of equipment Name of  the company 
UV / Vis Spectrophotometer     JASCO V-530. 
IR Spectrophotometer Jasco-FT-IR 8201 PC  
Differential scanning calorimeter  DSC-60 (Shimadzu, Tokyo, Japan) 
Optical Microscope and stage Micrometer    Erma. Japan 
Scanning Electron Microscope JSM 6400 
X-ray diffractrometer  Bruker AXS D8  
Dissolution apparatus Electrolab TDT-08L, USP XXIV 
Type I apparatus. Chennai. 
Remi Hi-speed motor                  Universal motors. Mumbai 
Digital balance                           Denver instruments  
pH tester 1 (water proof) Oakton instruments. 
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DRUG PROFILE 
    ACECLOFENAC 43-45 
 Aceclofenac is from the class of Non Steroidal Anti Inflammatory 
Drug (NSAID). It is a derivative of aryl acetic acid.   
 
Chemical name 
 [[[2-[(2, 6-Dichlorophenyl) amino] phenyl] acetyl] oxy] acetic acid.  
 
Empirical formula  
 C16H 13Cl2 NO4 
 
Chemical Structure    
                                        
CH2
O
O
CH2
COOH
NH
ClCl
  
Physical Characteristics  
 Colour: white. 
 Appearance: white, crystalline powder. 
 
Solubility    
 It is practically insoluble in water, freely soluble in    
 acetone, soluble in alcohol.  
Melting point :  149°-160°C. 
Molecular weight :  354.2 
Half life  :  4 hours.  
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Dose and Administration 
 The usual dose of aceclofenac is 100mg given orally twice daily. 
One tablet in the morning and the other in the evening. There is some 
evidence that the dose of aceclofenac should be reduced in patients with 
hepatic impairment and it is suggested that an initial daily dose of 100mg be 
used.    
 
Over dosage 
 There are no human data available on the consequences of 
aceclofenac over dosage. The symptoms could be nausea, vomiting, 
stomach pain, dizziness, somnolence, and headache 
 
PHARMACOKINETICS 
Absorption 
 Aceclofenac is absorbed rapidly and completely after oral 
administration. Peak plasma concentrations are reached approximately 1-3 
hours after an oral dose. The presence of food does not alter the extent of 
absorption of aceclofenac but the absorption rate is reduced. 
 
Distribution 
 Aceclofenac is highly protein bound (~99.7%). The plasma 
concentration of aceclofenac was approximately twice that in synovial fluid 
and multiple doses of drug in patients with knee pain and synovial fluid 
effusion. The volume of distribution is approximately 30L. 
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Metabolism 
 Aceclofenac is metabolized into a major metabolite, 4’- hydroxyl 
aceclofenac and to a number of other metabolites including 5-hydroxy 
aceclofenac, 4’- hydroxyl diclofenac, and 5- hydroxyl diclofenac. These 
other metabolites account for the fate of approximately 20% of each dose of 
aceclofenac. 
 
Excretion 
 Renal excretion is the main route of elimination of aceclofenac with 
70-80% of the administered dose found in the urine, mainly as the 
glucuronides of aceclofenac and its metabolites. Of each of dose of 
aceclofenac, 20% is excreted in the faeces. The plasma elimination half-life 
of the drug is approximately 4 hours 
 
Pharmacology 
 The mode of action of aceclofenac is largely based on the inhibition 
of prostaglandin synthesis.Aceclofenac is a potent inhibitor of the enzyme 
Cyclooxygenase (COX), which is involved in the production of 
prostaglandins. Aceclofenac has shown to exert effect on a variety of 
mediators of inflammation. The drug inhibits the synthesis of inflammatory 
cytokines interleukin (IL)-1β and inhibits Prostaglandin E2 (PGE2) 
production. In vitro data indicate inhibition of COX 1&2 by aceclofenac in 
whole blood assays; with selectively COX 2 is evident. 
 
 In contrast to some other NSAID’s aceclofenac has shown 
stimulatory effect on cartilage matrix synthesis that may be linked to the 
ability of the drug to inhibit (IL) - 1β activity. There is also evidence that 
aceclofenac stimulates the synthesis of IL-1 receptor antagonist in human 
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articular chondrocytes subjected to inflammatory stimuli and that 4’- 
hydroxyl aceclofenac has chondro protective properties attributable to 
suppression of (IL) - 1β mediated promatrix metallo proteinase production 
and proteoglycan release.  
 In patients with osteoarthritis of the knee, aceclofenac decreases 
pain, reduces diseased severity and improves the functional capacity of the 
knee. It reduced joint inflammation, pain intensity and the duration of 
morning stiffness in patients with rheumatoid arthritis. The duration of 
morning stiffness and pain intensity are reduced and spinal motility 
improved, by aceclofenac in patients with ankylosing spondylitis. 
 
Indications 
 Aceclofenac is indicated for the relief of pain and inflammation 
associated with rheumatoid arthritis, osteoarthritis and in ankylosing 
spondylitis.  
 
Contraindications 
 Aceclofenac should not be administered to patients hypersensitive to 
aceclofenac or other NSAID’s, or patients with history of aspirin or 
NSAID’s related allergic and to patients with anaphylactic reactions or with 
peptic ulcers or GI bleeding, moderate of severe renal impairment. 
 
Drug interactions 
 Drug interactions associated with aceclofenac are similar to those 
observed with other NSAID’s. Aceclofenac may increase plasma 
concentrations of lithium, digoxin and methotrexate, increase the activity of 
anti coagulants, inhibit activity of diuretics, enhance cyclosporine 
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nephrotoxicity and precipitate convulsions when co administered with 
quinolone antibiotics. The co administration of aceclofenac with other 
NSAID’s or corticosteroids may result in increased frequency of adverse 
events. 
Adverse drug reactions 
 Aceclofenac is well tolerated with most adverse events being minor 
and reversible and affecting mainly the GI system. Most common events 
includes dyspepsia, and abdominal pain, dizziness, vertigo, pruritus, rash 
and dermatitis have been reported with aceclofenac, but the incidence of 
these events is less than 5%. Increases blood urea nitrogen and a blood 
creatinine level have been reported with aceclofenac treatment. As with 
other NSAID’s, aceclofenac can elevate circulating levels of hepatic 
enzymes.  
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POLYMER PROFILE 
SODIUM ALGINATE46 
 Alginate is linear, naturally occurring polysaccharide, consisted of   
β-D-mannuronic acid and α-L-guluronic acid. The ability of alginate to 
form gel in the presence of multivalent ions has been utilized and the 
material to be encapsulated is added drop wise into the multivalent ion 
solution. The contact of droplets with multivalent ions results in 
instantaneous formation of gel spheres containing uniformly dispersed 
material throughout the cross linked alginate matrix.    
 
Non Proprietary Names 
 BP  -  Sodium alginate 
 Ph.Eur - Natrii aligns 
 USPNF -  Sodium alginate                         
 
Synonyms 
 Algin; alginic acid, sodium salt; kelcosol; keltone; protanal; sodium 
polymannuronate. 
 
Method of manufacturing 
 Alginic acid is extracted from brown seaweed and is neutralized with 
sodium bicarbonate to form sodium alginate. 
 
Chemical name  
 The chemical compound sodium alginate is the sodium salt of alginic 
acid.  
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Empirical Formula 
  NaC6H7O6 
Structural formula 13 
 
 
 
 
 
Description 
 Sodium alginate occurs as an odorless, tasteless, and white to pale 
yellowish brown colored powder. 
 
pH  
 Approximately 7.2 for a 1%w/v aqueous solution. 
 
Solubility 
  Practically insoluble in ethanol, ether, and chloroform. Also, 
practically insoluble in other organic solvents and aqueous acidic solutions 
in which the pH is less than 3, but it is slowly soluble in water to form a 
viscous colloidal solution. 
 
Viscosity (dynamic)  
 Various grades of sodium alginates are commercially available that 
yield aqueous solutions of varying viscosity. Typically, a 1%w/v aqueous 
solution at 20ºC will have a viscosity of 20-400 mPas (20- 400cp).Viscosity 
may vary depending upon concentration, pH, temperature, or the presence 
of metal ions and in general above pH 10, viscosity decreases. 
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Functional category 
 It is used as a stabilizing agent; suspending agent; tablet, capsule 
disintegrant; binder, viscosity modifier. 
 
Stability and storage conditions 
 Sodium alginate is a hygroscopic material, although, stable at low 
humidities and at cool temperatures. Aqueous solutions of sodium alginate 
are most stable at pH 4-10. Below pH 3, alginic acid is precipitated. Sodium 
alginate solutions are susceptible to microbial spoilage during storage, 
which may affect solution viscosity. Solutions are ideally sterilized using 
ethylene oxide, although filtration by using a 0.45µm filter has only a slight 
adverse effect on solution viscosity. Subsequent loss of viscosity due to 
depolarization was observed when sodium alginate was heated above 70°C. 
Preparations containing sodium alginate, for external use may be preserved 
by the addition of 0.1% chlorocresol, chloroxylenol, or parabens and if the 
medium is acidic, benzoic acid may be used. Bulk material should be stored 
in an airtight container in a cool and dry place. 
 
Incompatibilities 
 Sodium alginate is incompatible with acridine derivatives, crystal 
violet, phenyl mercuric acetate and nitrate, heavy metals and ethanol in 
concentrations greater than 5% w/v. Low concentrations of electrolytes 
cause an increase in viscosity but high electrolyte concentrations causing 
salting out of sodium alginate; salting out occurs if more than 4% of sodium 
chloride is present. 
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Application in pharmaceutical formulations 
 Sodium alginate is used in variety of oral and pharmaceutical   
formulations. In tablet formulations, sodium alginate may be used as both a 
binder and disintegrant; it has also been used as an diluents in capsule 
formulations and also been used in the preparation of sustained release oral 
formulations, since it can delay the dissolution of a drug from tablets, 
capsules, and aqueous suspensions.   
  
 Recently, sodium alginate has been used for the aqueous 
microencapsulation of drugs, in contrast with the more conventional 
microencapsulation techniques which use organic solvent systems. It has 
also been used in the formation of nanoparticles. 
  
 The adhesiveness of hydrogels prepared from sodium alginate has 
been investigated and the drug release from oral mucosal adhesive tablets 
based in sodium alginate has been reported. Hydrogel systems containing 
alginates have also been investigated for delivery of proteins and peptides.  
 
 Therapeutically, sodium alginate has been used in the combination 
with an H2 receptor antagonist in the management of gastroesophageal 
reflux and as a hemostatic agent in surgical dressings. Alginate dressings, 
used to treat exuding wounds often contain significant amounts of sodium 
alginate as this improves the gelling properties. Sodium alginate is also used 
in cosmetics and food products at concentrations given in Table 4. 
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TABLE: 4 General uses of sodium alginate 
Use Concentration (%) 
Pastes and creams 
        Stabilizer in Emulsions 
Suspending agent 
                  Tablet binder 
Tablet disintegrant 
5 - 10 
1 – 3 
1 – 5 
1 – 3 
2.5 - 10 
 
Safety 
 Sodium alginate is widely used in cosmetics, food products, and 
pharmaceutical formulations, such as topical products, including wound 
dressings. It is generally regarded as a nontoxic and nonirritant material, 
although excessive oral consumption may be harmful. The WHO has not 
specified an acceptable daily intake for alginic acid and alginate salts as the 
levels used in foods do not represent a hazard to health. 
 
Handling precautions 
 Sodium alginate may be irritant to eye or respiratory system if 
inhaled as dust; Eye protection, gloves, dust respirator are needed while 
handling. Sodium alginate should be handled in a well ventilated 
environment. 
 
Related substances 
 Alginic acid; calcium alginate; potassium alginate; propylene glycol 
alginate. 
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Calcium alginate 
Synonyms 
 Alginic acid, calcium salt, calcium polymannuronate, calginate.  
Comments 
 Calcium alginate is used similarly as sodium alginate in the 
preparation of sustained release formulations, preparations of beads, 
hydrogels and hemostatic wound dressings which can be washed off with 
sterile sodium chloride solution. The microencapsulation of live attenuated 
Bacillus Calmette Guerin (BCG) cells with in a calcium alginate matrix has 
also been reported. 
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CHITOSAN 47 
 Chitosan is a derivative of chitin and it is a unique polysaccharide 
and a hydrophilic polymer. 
Non Proprietary Names 
 BP: Chitosan hydrochloride 
 Ph Eur: Chitosan hydrochloridum 
Chemistry 
 Structural formula 
 
 
Chemical Name: poly- β-(1, 4) - 2- Amino- 2-deoxy-D-glucose 
 
Preparation 
 The principle derivative of chitin, namely Chitosan (C6H11O4N)n  is a 
unique polysaccharide and hydrophilic polymer which is taken from the 
chitin, a polysaccharide found in the exoskeletons of crustaceans. It is 
processed by removing the shells from shellfish such as shrimp, lobusters, 
and crabs. The shells are then ground into a pulverous powder. This powder 
is then deacelytated. This involves boiling Chitin in concentrated alkali 
(50%) for several hours. This will yield Chitosan with a degree of 
acetylation between 20-30%, the most popular commercial form of 
Chitosan. In such a Chitosan, the acetyl groups are uniformly distributed 
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along the polymer chain. This is in contrast with the Chitosan of similar 
degree of acetylation, but isolated from fungal cell walls in which the acetyl 
residues are grouped into clusters. Special chemical treatment is needed to 
obtain completely de-acetylated forms of Chitosan. 
 
Chitin 
 
Chitosan, partly acetylated (obtained by chemical methods) 
 
Chitosan, partly acetylated (isolated from fungal cell wall) 
 
Chitosan, completely de-acetylated (obtained by chemical methods) 
 
Functional category 
 It is used as a coating agent; disintegrant; film-forming agent; 
mucoadhesive; tablet binder; viscosity-increasing agent,etc. 
Chemical Character 
 Chitosan is a cationic polyamine with a high charge density at pH < 
6.5 so adheres to negatively charged surface and chelates metal ions. It is a 
linear polyelectrolyte with reactive hydroxyl and amino groups so available 
for chemical reaction and salt formation. Chitosan is a linear polysaccharide 
composed of randomly distributed β-(1-4)-linked D-glucosamine 
(deacetylated unit; D) and N-acetyle-D-glucosamine (acetyle unit; A). The 
percentage degree of deacetylation (%DA) of Chitin can be determined by 
NMR spectroscopy, and the %DA in commercial Chitosan is in the range 
60-100 %. The viscosity of a Chitosan solution primarily depend on the 
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average molecular weight of the polymer, which can be determined by size 
exclusion chromatography combined with light scattering detection. 
 The amino group in Chitosan has a pKa value of ≈6.5, thus chitosan 
is positively charged and soluble in acidic to neutral solution with a charge 
density depend on pH and the %DA. Numerous studies have demonstrated 
that the salt form, molecular weight, and degree of deacetylation as well as 
pH at which the chitosan is used all influence how this polymer is utilized 
in pharmaceutical application. Chitosan is incompatible with strong 
oxidizing agent. 
 
Typical properties 
 Chitosan is a cationic polyamine with a high charge density at 
pH<6.5. It is linear poly electrolyte with reactive hydroxyl and amino 
groups. The properties of chitosan relate to its poly electrolyte and 
polymeric carbohydrate character. The presence of a number of amino 
groups allows chitosan to react chemically with anionic systems, which 
results in alteration of physicochemical characteristics of such 
combinations. 
 
Acidity/alkalinity pH=4 – 6 (1%w/v aqueous solution) 
Density 1.35 – 1.49 g/cm3 
Particle size distribution  < 30 µm 
 
Stability and Storage condition 
 Chitosan is a stable material at room temperature although it is 
hygroscopic after drying. Chitosan should be stored in a tightly closed 
container in a cool and dry place. 
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Incompatibilities 
 Chitosan is incompatible with strong oxidizing agents. 
 
Safety 
 Chitosan is being investigated widely for use as an excipient in oral 
and other pharmaceutical formulations. It is also used in cosmetics. 
Chitosan is generally regarded as biodegradable, nontoxic and nonirritant 
material. It is biocompatible with both healthy and infected skin. 
 
Applications 
¾ Used in sustained drug delivery application. 
¾ Used as a components of mucoadhesive dosage forms, rapid release 
dosage forms, improved peptide delivery, colonic drug delivery 
systems, and use for gene delivery. 
¾ It is processed into several pharmaceutical forms including gels, 
films, beads, microspheres tablets and coating for liposomes. 
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FORMULATION OF SODIUM ALGINATE BEADS 
CONTAINING ACECLOFENAC27& 34 
 
 The beads of aceclofenac were prepared by ionotropic gelation 
technique as described in Sahoo S.K. et al. 100ml of Sodium Alginate (SA) 
solution at different concentrations were prepared by stirring sodium 
alginate powder in deionized water for 30 minutes then, an accurately 
weighed quantity of aceclofenac was added to afford homogenous 
dispersions. The SA-drug dispersion were then added drop wise into a 
100ml of cross linking solution (different concentration and type) using a 
10ml of hypodermic syringe fitted with a 20 gauge needle and stirred at  
500 rpm. The formed alginate beads were cured at different time intervals. 
On expiration of this period the solution of cross linking agent was decanted 
and the alginate beads were washed repetitively for three times with 50ml 
deionized water. The alginate beads were thereafter dried at 60°C for                 
2 hours in a hot air oven. Similarly, chitosan – alginate beads were also 
prepared with a defined amount of chitosan, previously dissolved in acetic 
acid solution which was then added in the cross linking solution. The 
variables chosen in the present work includes concentration of sodium 
alginate, concentration of cross-linking agent, different curing time 
intervals, different cross linking agents, and addition of chitosan were 
studied. The details of the formulations prepared were given in the Table 5. 
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TABLE: 5 COMPOSITIONS OF DIFFERENT BATCHES OF ALGINATE 
BEADS PREPARED 
 
Formulation 
code 
Drug 
(mg) 
Sodium 
alginate 
(%w/v) 
Cross-
linking 
type 
Cross-
linking 
(%w/v) 
Curing 
time 
(min) 
F1 200 2.5 CaCl2 3 30 
F2 200 2.5 CaCl2 3 30 
F3 200 2.5 CaCl2 3 30 
F4 200 2.5 CaCl2 3 30 
F5 200 2.5 CaCl2 3 30 
F6 200 2.5 CaCl2 1 30 
F7 200 2.5 CaCl2 2 30 
F8 200 2.5 CaCl2 4 30 
F9 200 2.5 CaCl2 5 30 
F10 200 2.5 CaCl2 3 15 
F11 200 2.5 CaCl2 3 60 
F12 200 2.5 CaCl2 3 120 
F13 200 2.5 CaCl2 3 240 
F14 200 2.5 BaCl2 3 30 
F15 200 2.5 Al2(SO4)3 3 30 
F16 200 2.5 
Chitosan+ 
CaCl2 
1.5 +1.5 30 
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COMPATIBILITY STUDIES 
 One of the requirements for the selection of suitable polymers or 
carriers for pharmaceutical formulation is its compatibility. Therefore in the 
present work a compatibility study was done by using Infra Red 
spectroscopy (IR) and Differential Scanning Calorimetry (DSC) to find out 
if there is any possible chemical interaction between aceclofenac and the 
polymers. 
 
IR SPECTRAL ANALYSIS  
 Weighed amount of the drug was mixed thoroughly with 100mg of 
potassium bromide (dried at 40° - 50° C) and compressed under 10 ton 
pressure in a hydraulic press to form a pellet which was then scanned from 
4000 - 400-1cm using FTIR 8201 PC spectrophotometer. The same 
procedure was repeated for polymers and other formulations prepared. The 
IR spectrum of aceclofenac and polymer was compared with IR spectrum of 
prepared formulation.  
 
DIFFERENTIAL SCANNING CALORIMETRY (DSC) 48 
 Differential Scanning Calorimetry analysis was used to characterize 
the thermal behavior of the drug substances. It was performed by using 
DSC-60 (Shimadzu, Tokyo, Japan) calorimeter to study the thermal 
behavior of selected formulations. The instrument comprised of calorimeter 
(DSC 60), flow controller (FCL60), thermal analyzer (TA 60) and operating 
software (TA 60). The samples were heated in hermetically sealed 
aluminum pans under nitrogen flow (30 ml/min) at a scanning rate of 
5ºC/min from 24±1ºC to 300ºC. An empty aluminum pan, sealed in the 
same way as the sample, was used as a reference.  
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PHYSICAL CHARACTERIZATION 
 
DETERMINATION OF PARTICLE SIZE AND SIZE DISTRIBUTION 
ANALYSIS 
 The particle size and distribution analysis were determined using an 
optical microscope. In this method a slide containing alginate beads were 
taken and 100 beads were subjected for particle size analysis using a 
calibrated optical micrometer. Each formulation were then evaluated in 
triplicate. 
 
Standardization of eye piece micrometer49 
 Calibrate the eyepiece micrometer with the help of the stage 
micrometer (standard). Note the division of the eye piece micrometer scale 
and stage micrometer scale which coincide with each other, use the 
following formula to asses how much is one division of eye piece 
micrometer. 
One division of stage micrometer = 10µ 
rmicromete eyepiece ofdivision  ofNumber 
10 X micrometerstageofdivision ofNumber micrometer eyepiece ofdivision  1 =  
       
 After obtaining the required data like frequency of particle in each 
size range (number distribution), the statistical diameters were calculated 
using the following Edmundson equation. The Table 6 given below 
explains how the statistical diameters were calculated. 
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n = number of particles in a size range in µm 
d = mid point in a size range 
p = an index related to size of an individual particle represents. 
If p =1, 2, 3 represents length, surface, volume respectively 
p = positive –arithmetic mean 
p = negative –harmonic mean 
p = zero – geometric mean 
f = 0,1,2,3  
Table: 6 Statistical diameters 
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P f Type of mean Size parameter Frequency 
Mean 
Diameter 
⎟⎟
⎟
⎠
⎞
⎜⎜
⎜
⎝
⎛
∑
∑
n
nd  1 0 Arithmetic Length Number 
Length – 
number mean 
din 
∑
∑
n
nd 2  2 0 Arithmetic Surface Number 
Surface – 
number mean 
dsn 
3
3
∑
∑
n
nd  3 0 Arithmetic Volume Number 
Volume– 
number mean 
dvn 
∑
∑
2
3
nd
nd
 1 2 Arithmetic Length Surface 
Volume – 
Surface or 
surface – 
weighted 
mean, dvs 
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SCANNING ELECTRON MICROSCOPY 
            The purpose of the Scanning Electron Microscope (SEM) study was 
to obtain the surface topographical characterization of the beads. SEM 
photographs of prepared formulations were taken with (Instrument JSM-
6390) at different magnification ranging from 30 to 5000X at room 
temperature. The samples were mounted on double-sided adhesive tape that 
has previously been secured on copper stubs. The acceleration voltage was 
maintained at 20kv, with a Secondary Electron Image (SEI) as a detector. 
 
X-RAY DIFFRACTROMETRY 27 (X-RD) 
 The X-ray diffraction patterns of pure drug and the selected 
formulation were recorded using a X-ray diffractrometry which was carried 
out to investigate the effect of microencapsulation process on crystallinility 
of drug. The X-RD patterns of drug powder and drug loaded beads were 
recorded using Bruker AXS D8 Advance X-ray diffractometer with a 
copper target. The conditions were: voltage -30 kV, current -30 mA, 
scanning speed -1/min. Temperature of acquisition: room temperature; 
Detector: scintillation counter detector.  
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DRUG CONTENT ANALYSIS 
 
DETERMINATION OF DRUG ENTRAPMENT EFFICIENCY17 
 Fifty milligrams of drug loaded alginate beads from each batch was 
placed in 100 ml conical flask containing 50 ml of phosphate buffer         
(pH 7.4). The beads were agitated on mechanical shaker for 24 hours, to 
promote swelling and break up of the cross - linked structure. Then 
solutions were filtered and the drug was quantified at 274 nm 
spectrophotometrically after appropriate dilution with buffer. The 
Entrapment Efficiency (EE) was determined by using the following 
empirical relationship. Each determination was performed in triplicate 
manner. 
Entrapment Efficiency (%) = Actualdrugcontent (AC) x100
Theoreticaldrugcontent (TC)
 
AC -   Actual quantity of drug present in the beads  
TC - 100% theoretical quantity of drug present in the beads  
 (actual initial dose) 
 
DRUG RELEASE STUDIES 
 
IN VITRO DRUG RELEASE STUDIES27 
 100 mg of drug loaded alginate beads were evaluated for in vitro 
drug release. The study was carried out in the USP XXIV Type I apparatus 
using 900ml phosphate buffer (pH 7.4) solution and rotated at constant 
speed (75 rpm) and the temperature of the medium was  maintained at 
37°±0.5°C for 8 hours. A muslin cloth was tied over the basket to prevent 
the slippage of beads from the basket. An aliquot of the sample (5ml) was 
periodically withdrawn at the regular time intervals (0,0.5,1,2,4,6 & 8 hrs) 
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and an equal volume was replaced with fresh dissolution medium. The test 
samples were filtered and analyzed spectrophotometrically at 274 nm after 
appropriate dilution with buffer. The study was performed in triplicate for 
each batch. The percentage drug released at different time intervals were 
calculated. The in vitro drug release profiles were obtained by plotting the 
percentage release Vs time in hours. 
 
DISSOLUTION KINETICS OF DRUG RELEASE 50 
 
 To study the release kinetics, data obtained from in vitro drug release 
studies were plotted in various kinetic models:  
Zero order (Equation 1) as cumulative amount of drug released vs time,  
 
First order (Equation 2) as log cumulative percentage of drug remaining vs 
time,  
 
Higuchi’s model (Equation 3) as cumulative percentage of drug released vs 
square root of time and 
 
 Korsmeyer’s (Equation 4) log cumulative percentage of drug released vs. 
log time 
         C = K0 t.            (Equation1) 
 
where  K0 is the zero-order rate constant expressed in units of   
  concentration/time and t is the time in hours. 
 A graph of concentration vs time would yield a straight line with a slope 
equal to K0 and intercept the origin of the axes.  
    [ ]kt/2.3030logCclog −=           (Equation2) 
where   C0 is the initial concentration of drug,  
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    k is the first order constant, and t is the time.  
     Q = 2
1
Kt               (Equation3) 
where   K is the constant reflecting the design variables of the system 
  and t is the time in hours. Hence, drug release rate is 
proportional to the reciprocal of the square root of time. 
 Drug release were plotted in Korsmeyer et al’s equation (Equation 4) 
as log cumulative percentage of drug released vs log time, and the exponent 
n was calculated through the slope of the straight line. 
 
    nt KtMM =∞     (Equation4) 
where  Mt/M∞ is the fractional solute release, 
   t is the release time, K is a kinetic constant. 
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ANALYTICAL METHODS 
 
DEVELOPMENT OF CALIBRATION CURVE FOR ACECLOFENAC 
Preparation of Buffers 
                The phosphate buffer solution of pH 7.4 was prepared as per 
procedures described in Indian Pharmacopoeia51 1996 and the pH was 
confirmed by using a digital pH meter. 
Preparation of aceclofenac stock solution 
 100mg of aceclofenac was accurately weighed and transferred to 
100ml volumetric flask, and it was dissolved in phosphate buffer (pH 7.4) 
and the volume was made upto 100ml using the buffer which gives 1mg/ml 
concentration.10ml of the above solution was withdrawn and the volume 
was made upto 100ml by phosphate buffer to give 100mcg/ml which will 
be used as a stock solution. 
Preparation of working standard solution 
 From the stock solution further dilutions were made to obtain                       
(5, 10, 15, 20, 25, 30, and 40mcg/ml) by using phosphate buffer. The 
absorbance's of the solutions were measured at 274 nm using UV 
spectrophotometer against blank (phosphate buffer). 
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The graph was plotted against concentration (µg/ml) vs. absorbance. The 
details of the solutions prepared were given in the Table 7. 
 
TABLE: 7 STANDARD SOLUTION DETAILS 
 
S.No 
Volume of 
stock solutions 
(100 µg /ml) 
 
Volume of 
buffer 
solutions 
(ml) 
Final 
volume 
(ml) 
Final 
concentration 
(µg/ml) 
1 0.5 9.5 10 05 
2 1.0 9.0 10 10 
3 1.5 8.5 10 15 
4 2.0 8.0 10 20 
5 2.5 7.5 10 25 
6 3.0 7.0 10 30 
7 4.0 6.0 10 40 
 
 
 STANDARD GRAPH   OF ACECLOFENAC 
  An attempt was made to obtain to conform the λmax value by 
scanning of the solutions prepared with different solvents were done and 
reported27,17 λmax was confirmed as 274 nm.  
 
 The calibration curve obtained was found to be linear with the 
selected concentrations and it was reported in Table 8 and Fig 4  
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 It obeys the Beer’s-Lambert limit 5 – 30 µg/ml regression equation 
(Absorbance =0.0024+0.0247 *concentration), the value of correlation              
co - efficient for aceclofenac was found to be 0.9998. This correlation                 
co - efficient suggest the level of precision of the method. 
 
TABLE: 8 Standard graph of aceclofenac in phosphate buffer pH 7.4 
S.No Concentration (µg/ml) Absorbance at 274 nm 
1 0 0 
2 5 0.1305 
3 10 0.2496 
4 15 0.3713 
5 20 0.4987 
6 25 0.6108 
7 30 0.7507 
8 40 0.9923 
 
FIG: 4 Standard graph of aceclofenac with phosphate buffer pH 7.4 
STANDARD GRAPH OF ACECLOFENAC
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 Absorbance=A + B*Concentration   A=0.0024  B=0.0247 
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SUMMARY 
  
 The current study “FORMULATION, PHYSICAL 
CHARACTERIZATION AND IN VITRO RELEASE STUDIES OF 
ACECLOFENAC ALGINATE BEADS PREPARED BY 
IONOTROPIC GELATION FOR SUSTAINED RELEASE” was to 
develop suitable particulate system of aceclofenac for sustained 
release system by the influence of varying the concentration of sodium 
alginate, concentration of calcium chloride, different curing time 
intervals, different cross linking agents and addition of chitosan to 
calcium chloride were also studied. The results obtained from the 
above study can be summarized as follows. 
" Literatures pertaining to alginate beads, cross linking agents, 
chitosan and drug aceclofenac were surveyed thoroughly and 
documented. 
" Standard graph was prepared by using phosphate buffer (pH 7.4) and 
analyzed by UV spectrophotometer at 274 nm. It gives linear with 
the selected concentrations. 
" Optimization of process parameters stirring speed, bore diameter of 
syringe, drying time were done. 
" Alginate beads containing aceclofenac and varying the concentration 
of sodium alginate, concentration of cross linking agent, different 
curing time interval, different cross linking agents and addition of 
chitosan to calcium chloride were prepared by ionotropic gelation 
and analysed. 
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COMPATIBILITY STUDIES 
IR spectral analysis  
 The IR spectrum revealed that there was no interaction between the 
drug and the polymer.  
DSC thermogram analysis 
 The thermogram of the prepared formulation revealed that the drug 
was uniformly dispersed at the molecular level in the beads.  
 
PHYSICAL CHARACTERIZATION 
Particle size and size distribution analysis  
" The particle size distribution of each formulation was very well 
 within a narrow size range. 
" An increase in the concentration of sodium alginate the average 
 mean diameter of the beads were increased. 
" The particle size would have been larger if the same was air dried 
 which may be because of in complete dehydration of the formed 
 beads.  
" The size of the beads were increased with addition of chitosan in the 
 cross linking solution. This is probably due to extra coating 
 provided by the adding chitosan. 
" No significant variations in particle size of the alginate beads 
 prepared using increased concentrations of cross – linking agent, 
 curing time and different type of cross linking agent. 
Scanning electron microscope  
" In all formulations, the shape of the alginate beads was more or less 
 spherical and the exterior surfaces were rough. 
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X-Ray Diffraction 
" The X-ray diffraction study exhibited that reduction in both number 
 and intensity of peaks compared to plain aceclofenac indicating 
 the decrease in crystallinity or partial amorphization of the drug 
 in prepared alginate  beads.  
 
" Thus XRD data supports the DSC studies which indicated the 
 decreased crystallinity of drug in the prepared alginate beads. 
 
DRUG CONTENT ANALYSIS 
" Increasing the concentration of sodium alginate resulted in, increase 
in drug entrapment this is due to decreased drug loss from the highly 
viscous polymer gel.  
" Increasing the concentration of cross linking agent resulted in, 
increase in drug entrapment this is due to availability of active 
calcium binding sites in the polymeric chain.  
" The entrapment efficiency of formulations were slightly decreased 
with increasing the curing time.  
" The entrapment efficiencies were higher for the formulations 
prepared with cross – linking agent barium chloride and aluminium 
sulphate as compared to the beads cross - linked with calcium 
chloride. This may be due to the extent and apparent cross  - linking 
density in the beads in the presence of Al3+ and Ba2+. 
" By the addition of chitosan the drug encapsulation was increased. 
This was probably due to increased ionic interactions between the 
carboxylate groups in the alginate and the protonated amine groups 
in the chitosan. 
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 IN VITRO DRUG RELEASE STUDIES  
" Increase in the concentration of sodium alginate the drug release rate 
becomes more sustained. This probably due to the number of the 
apparent cross - linking points and density formed within the calcium 
alginate beads. 
" Increased in the concentration of calcium chloride more sustained 
effect was produced, this may be due to formation of strong rigid gel 
beads which may reduce the penetration of dissolution medium. 
" By using the Ba2+ and Al3+ in cross - linking solutions more 
sustained effect was produced compared to calcium alginate beads.  
" The release behavior of alginate beads produced by ionic gelation 
with different cross – linking agents depend upon the valency and 
size of the cations of the respective cross – linking agent. 
" With the addition of chitosan in the cross - linking solution, the 
release of drug from chitosan alginate beads was very low, because it 
forms the outer coat. 
 
KINETICS OF DRUG RELEASE  
" The results indicated that the drug release from formulation followed 
the diffusion controlled model as described by Higuchi’s square root 
of time equation. 
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CONCLUSION 
 
 It can be concluded from the above investigation that the proper 
selection of formulation parameters are important to achieve high 
entrapment efficiency and to sustained the release of drug from alginate 
beads. Ionotropic gelation technique can be successfully used for 
preparation of aceclofenac alginate beads. Aceclofenac releases from the 
beads were influenced by sodium alginate, calcium chloride concentration. 
By increasing the polymer and cross linking concentration entrapment 
efficiency increased and drug release were more sustained effect. And also 
by the addition of different cross linking agent, chitosan in the cross linking 
solution can very much alter the drug encapsulation and release 
characteristics. Effect of curing time on the drug release, encapsulation 
efficiency was less significant. Therefore, more formulation studies are 
needed to design the best sustained release formulation. 
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FUTURE WORK 
 
 The study can be extended by putting an effort to increase the 
entrapment efficiency, release characteristics and standardizing the process 
variables like temperature, addition of polymers to the cross linking solution, 
volume of the internal phase, processing time, type of surfactant in the external 
phase can also be studied and their effect on the size of the beads formed, drug 
entrapment efficiency, and in-vitro and in-vivo release studies can also be 
performed, to standardize a successful formulation. 
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SR  Sustained Release  
SA  Sodium Alginate  
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CaCl2  Calcium Chloride 
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Abstract 
ABSTRACT 
 
 
 The objective of the present study was to microencapsulate the anti-
inflammatory drug (aceclofenac) to provide sustained release and minimizing 
or eliminating drug release in the upper gastro intestinal tract. Alginate beads 
of aceclofenac were formulated by ionotropic gelation and the variables 
studied includes the effect of concentration of sodium alginate, concentration 
of cross linking agent (CaCl2), different curing time intervals, different cross 
linking agents, and addition of chitosan with CaCl2 were evaluated with respect 
to particle size, surface characteristics, entrapment efficiency and in vitro 
release behaviors. Infra Red spectroscopic study confirmed the absence of any 
drug interaction. Differential Scanning Calorimeter (DSC) analysis revealed 
that the drug was uniformly dispersed in the alginate beads. The mean particle 
size increases with increasing the polymer concentration and addition of 
chitosan. The shape of the alginate beads have acceptable sphericity and 
surfaces were rough which were confirmed by Scanning Electron Microscope 
photographs. The X-ray diffraction data supports the DSC studies which 
indicated the decreased crystallinity of drug in the prepared alginate beads. The 
entrapment efficiency in different formulation varied from 62.18% to 87.96%. 
The in vitro release profiles were also altered significantly by changing various 
parameters. The kinetic modeling of the release data indicates that aceclofenac 
released from the alginate release from the alginate beads followed by the 
Matrix Higuchi model. From the study it can be concluded that aceclofenac 
could be successfully prepared by ionotropic gelation technique with high 
entrapment efficiency and prolonged release characteristics.   
